Is venous thromboprophylaxis necessary in patients undergoing minimally invasive surgery for a gynecologic malignancy?

Objectives. Current recommendations for the use of venous thromboprophylaxis in patients undergoing minimally invasive surgery (MIS) for a gynecologic malignancy are derived from patients undergoing open surgery. Our objective was to determine the 30-day prevalence of symptomatic venous thromboembolism (VTE) after laparoscopic gynecologic oncology procedures in patients who received no thromboprophylaxis. Methods. Between January 2006 and September 2013, women who underwent MIS for endometrial, cervical or ovarian cancer at a single institution were included. Data on patient demographics, diagnosis, comorbidities, perioperative characteristics, use of thromboprophylaxis, and diagnosis of VTE were collected retrospectively. Results. Of the 419 patients who underwent MIS for a gynecologic cancer, 352 (84%) received no VIE prophylaxis. At least a total laparoscopic hysterectomy (simple or radical) or pelvic lymph node dissection was performed in 95% of these patients. The median length of surgery was 137 min and 95% of patients were discharged home within 1 day of surgery. The rate of VTE in the 352 untreated patients was 0.57% (1 pulmonary embolism and 1 deep vein thrombosis). There were no VIE diagnosed within 30 days of surgery in the 67 patients who received anticoagulant thromboprophylaxis. Conclusion. The rate of VIE is low in patients undergoing minimally invasive surgery for a gynecologic malignancy despite no VIE prophylaxis. The benefits of routine use of VIE prophylaxis in this population are questionable. (C) 2014 Elsevier Inc. All rights reserved.